News

Sandu Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 5 May 2026, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.

Net profit of Sandu Pharmaceuticals declined 87.88% to Rs 0.04 crore in the quarter ended March 2026 as against Rs 0.33 crore during the previous quarter ended March 2025. Sales rose 19.76% to Rs 16.85 crore in the quarter ended March 2026 as against Rs 14.07 crore during the previous quarter ended March 2025.For the full year,net profit rose 14.19% to Rs 1.77 crore in the year ended March 2026 as against Rs 1.55 crore during the previous year ended March 2025. Sales rose 4.08% to Rs 69.93 crore in the year ended March 2026 as against Rs 67.19 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales16.8514.07 20 69.9367.19 4 OPM %3.323.20 -4.304.11 - PBDT0.900.49 84 3.342.83 18 PBT0.740.34 118 2.662.16 23 NP0.040.33 -88 1.771.55 14 Powered by Capital Market - Live News

Sandu Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 May 2026.

Net profit of Sandu Pharmaceuticals rose 75.00% to Rs 0.98 crore in the quarter ended December 2025 as against Rs 0.56 crore during the previous quarter ended December 2024. Sales rose 2.12% to Rs 18.76 crore in the quarter ended December 2025 as against Rs 18.37 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales18.7618.37 2 OPM %5.605.44 - PBDT1.030.99 4 PBT0.860.80 8 NP0.980.56 75 Powered by Capital Market - Live News

Sandu Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6 February 2026.Powered by Capital Market - Live News